Correlation Between Lyra Therapeutics and Ultragenyx

Can any of the company-specific risk be diversified away by investing in both Lyra Therapeutics and Ultragenyx at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Lyra Therapeutics and Ultragenyx into the same portfolio, which is an essential part of the fundamental portfolio management process.

By analyzing existing cross correlation between Lyra Therapeutics and Ultragenyx, you can compare the effects of market volatilities on Lyra Therapeutics and Ultragenyx and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Lyra Therapeutics with a short position of Ultragenyx. Check out your portfolio center. Please also check ongoing floating volatility patterns of Lyra Therapeutics and Ultragenyx.

Diversification Opportunities for Lyra Therapeutics and Ultragenyx

0.72

Correlation Coefficient

Lyra Therapeutics  Ultragenyx

Poor diversification

The 3 months correlation between Lyra and Ultragenyx is 0.72. Overlapping area represents the amount of risk that can be diversified away by holding Lyra Therapeutics and Ultragenyx in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Ultragenyx and Lyra Therapeutics is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Lyra Therapeutics are associated (or correlated) with Ultragenyx. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Ultragenyx has no effect on the direction of Lyra Therapeutics i.e., Lyra Therapeutics and Ultragenyx go up and down completely randomly.

Pair Corralation between Lyra Therapeutics and Ultragenyx

Given the investment horizon of 90 days Lyra Therapeutics is expected to under-perform the Ultragenyx. In addition to that, Lyra Therapeutics is 2.33 times more volatile than Ultragenyx. It trades about -0.02 of its total potential returns per unit of risk. Ultragenyx is currently generating about 0.09 per unit of volatility. If you would invest  3,905  in Ultragenyx on September 12, 2024 and sell it today you would earn a total of  1,004  from holding Ultragenyx or generate 25.71% return on investment over 90 days.

Time Period	3 Months [change]
Direction	Moves Together
Strength	Significant
Accuracy	99.2%
Values	Daily Returns

Lyra Therapeutics  vs.  Ultragenyx

Lyra Therapeutics

Risk-Adjusted Performance

0 of 100

Very Weak

Over the last 90 days Lyra Therapeutics has generated negative risk-adjusted returns adding no value to investors with long positions. Despite latest weak performance, the Stock's basic indicators remain strong and the current disturbance on Wall Street may also be a sign of long term gains for the company investors.

Ultragenyx

Risk-Adjusted Performance

0 of 100

Very Weak

Over the last 90 days Ultragenyx has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of weak performance in the last few months, the Stock's basic indicators remain rather sound which may send shares a bit higher in January 2025. The latest tumult may also be a sign of longer-term up-swing for the firm shareholders.

Pair Trading with Lyra Therapeutics and Ultragenyx

The main advantage of trading using opposite Lyra Therapeutics and Ultragenyx positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Lyra Therapeutics position performs unexpectedly, Ultragenyx can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Ultragenyx will offset losses from the drop in Ultragenyx's long position.

The idea behind Lyra Therapeutics and Ultragenyx pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.

Check out your portfolio center.

Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the ETF Categories module to list of ETF categories grouped based on various criteria, such as the investment strategy or type of investments.